Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Clinical academia is on a steep decline globally. In the UK, a 6% reduction in the number of clinical academics since 2012 has been reported, with the number of senior lecturer level researchers ...

The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023, ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

The vaccine is the only protein-based COVID shot still in use in the U.S. This approval would allow the vaccine to stay on ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

The best high-yield dividend stocks we recommend are The Brookfield Renewable Partners L.P., Pfizer, and Healthpeak ...